Why Manitowoc, Endocyte, and Seattle Genetics Tumbled Today
Stocks generally disappointed investors on Friday as the Ukrainian situation trumped strong jobs data, but these three stocks performed much worse than the broader market. Find out why.
Why Seattle Genetics, Inc. Shares Soured
Seattle Genetics shares sink despite topping Wall Street's expectations in the first quarter. See what has investors up in arms and what you should do about it.
Seattle Genetics' Revenue Rises 19% on Adcetris Sales Growth
Antibody-drug conjugate developer Seattle Genetics delivers strong sales gains from lead drug Adcetris despite a flat year-over-year net loss.
Seattle Genetics Achieves Milestones Under Collaboration with Takeda for Achieving First Commercial
Seattle Genetics Achieves Milestones Under Collaboration with Takeda for Achieving First Commercial Sales of ADCETRIS
5 Biotechs With Prostate Cancer Treatments Worth Watching
Prostate cancer is now the second leading cause of cancer-specific deaths among men in the United States. Here are five biotechs aiming to meet this challenge with a diversity of promising new therapies.